Texas Top Legal Officer Files Lawsuit Against Tylenol Makers Concerning Autism Spectrum Allegations

Judicial Proceedings
Ken Paxton, a Trump ally campaigning for the United States Senate, alleged the drug companies of withholding safety concerns of Tylenol

The top legal official in Texas Paxton is suing the producers of acetaminophen, claiming the corporations hid alleged dangers that the drug posed to children's brain development.

This legal action comes four weeks after President Donald Trump advocated an unverified association between using acetaminophen - also known as acetaminophen - during pregnancy and autism in young ones.

Paxton is taking legal action against the pharmaceutical giant, which once produced the medication, the only pain reliever approved for expectant mothers, and Kenvue, which now manufacturers it.

In a statement, he claimed they "misled consumers by gaining financially from discomfort and marketing drugs without regard for the risks."

The company asserts there is insufficient reliable data linking Tylenol to autism.

"These corporations misled for generations, knowingly endangering millions to increase profits," Paxton, a Republican, said.

The manufacturer said in a statement that it was "deeply concerned by the perpetuation of misinformation on the security of paracetamol and the potential impact that could have on the health of American women and children."

On its online platform, Kenvue also said it had "regularly reviewed the applicable studies and there is lacking reliable evidence that demonstrates a established connection between taking acetaminophen and autism spectrum disorder."

Associations speaking for doctors and healthcare providers agree.

The leading OB-GYN organization has said acetaminophen - the key substance in Tylenol - is among limited choices for women during pregnancy to treat discomfort and elevated temperature, which can pose serious health risks if not addressed.

"In multiple decades of investigation on the use of paracetamol in gestation, not a single reputable study has conclusively proven that the usage of acetaminophen in any trimester of gestation leads to neurodevelopmental disorders in young ones," the group stated.

The court filing mentions latest statements from the Trump administration in claiming the drug is allegedly unsafe.

In recent weeks, the former president caused concern from medical authorities when he instructed expectant mothers to "resist strongly" not to use Tylenol when sick.

The FDA then released a statement that physicians should consider limiting the use of Tylenol, while also stating that "a causal relationship" between the medication and autism spectrum disorder in children has remains unverified.

Health Secretary RFK Jr, who oversees the Food and Drug Administration, had promised in April to undertake "extensive scientific investigation" that would determine the source of autism spectrum disorder in a limited time.

But experts cautioned that identifying a single cause of autism spectrum disorder - thought by researchers to be the consequence of a complicated interplay of inherited and external influences - would prove challenging.

Autism is a form of lifelong neurodivergence and impairment that impacts how persons encounter and relate to the surroundings, and is recognized using physician assessments.

In his legal document, the attorney general - who supports Trump who is campaigning for US Senate - alleges the manufacturer and J&J "intentionally overlooked and tried to quiet the science" around paracetamol and autism spectrum disorder.

This legal action seeks to make the firms "remove any commercial messaging" that asserts acetaminophen is secure for women during pregnancy.

The Texas lawsuit echoes the concerns of a collection of guardians of young ones with autism and ADHD who sued the manufacturers of Tylenol in two years ago.

The court dismissed the case, stating studies from the parents' expert witnesses was lacking definitive proof.

Sarah Dudley
Sarah Dudley

A passionate gamer and tech enthusiast, Elara shares in-depth reviews and industry insights from years of experience.